» Articles » PMID: 17130178

Potential Utility of Plasma Fatty Acid Analysis in the Diagnosis of Cystic Fibrosis

Overview
Journal Clin Chem
Specialty Biochemistry
Date 2006 Nov 30
PMID 17130178
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: An altered distribution of fatty acids in cells and tissues is found in patients with cystic fibrosis (CF). In this study, we assessed the potential role of plasma fatty acid analysis in the diagnosis of CF.

Methods: In this 2-part study, we first used gas chromatography-mass spectrometry to analyze fatty acids in plasma from 13 CF patients and 11 controls without CF. We then used the fatty acid distribution data to identify the fatty acids or multiple fatty acid calculations most effective in identifying CF patients. Part 2 of the study was a blinded analysis of 10 CF patients and 9 controls to directly test the effectiveness of the diagnostic parameters for CF identified from the plasma fatty acid analysis.

Results: In the nonblinded trial, the multiplication product of (18:2 n-6) x (22:6 n-3) (each as percentage of total plasma fatty acid) was the most effective indicator for distinguishing patients with CF from controls (P = 0.0003). In part 2 (the blinded trial), this multiplication product was also the most effective indicator for distinguishing CF patients from controls (P = 0.0008).

Conclusions: The product of (18:2 n-6) x (22:6 n-3) is effective for distinguishing CF patients from persons without CF. This diagnostic marker may have value as an alternative to the sweat chloride test in selected patients being evaluated for CF.

Citing Articles

Fatty acid abnormalities in cystic fibrosis-the missing link for a cure?.

Drzymala-Czyz S, Walkowiak J, Colombo C, Alicandro G, Storrosten O, Kolsgaard M iScience. 2024; 27(11):111153.

PMID: 39620135 PMC: 11607544. DOI: 10.1016/j.isci.2024.111153.


DeltaF508 CFTR Hetero- and Homozygous Paediatric Patients with Cystic Fibrosis Do Not Differ with Regard to Nutritional Status.

Medza A, Kazmierska K, Wielgomas B, Konieczna L, Oledzka I, Szlagatys-Sidorkiewicz A Nutrients. 2021; 13(5).

PMID: 33919435 PMC: 8143312. DOI: 10.3390/nu13051402.


Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study.

OConnor M, Thomsen K, Brown R, Laposata M, Seegmiller A Prostaglandins Leukot Essent Fatty Acids. 2016; 113:46-49.

PMID: 27720040 PMC: 5088712. DOI: 10.1016/j.plefa.2016.08.011.


The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study.

OConnor M, Seegmiller A J Cyst Fibros. 2016; 16(1):132-138.

PMID: 27473897 PMC: 5241173. DOI: 10.1016/j.jcf.2016.07.006.


Lessons learned from metabolomics in cystic fibrosis.

Muhlebach M, Sha W Mol Cell Pediatr. 2015; 2(1):9.

PMID: 26542299 PMC: 4883209. DOI: 10.1186/s40348-015-0020-8.